Interactions between SARS coronavirus 2 papain‐like protease and immune system: A potential drug target for the treatment of COVID‐19. (10th August 2021)

• Record Type: Journal Article
• Authors: Mahmoudvand, Shahab; Shokri, Somayeh
• Is Part Of: Scandinavian journal of immunology. Volume 94:Number 4(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-10
• Subjects: COVID‐19 -- DeISGylating -- deubiquitinating -- papain‐like protease -- severe acute respiratory syndrome coronavirus 2; Immunology -- Periodicals; 571.96
• DOI: 10.1111/sji.13044
• Languages: English
• ISSNs: 0300-9475

Abstract

Abstract: Coronaviruses (CoVs) are a large family of respiratory viruses which can cause mild to moderate upper respiratory tract infections. Recently, new coronavirus named as Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been identified which is a major threat to public health. Innate immune responses play a vital role in a host's defence against viruses. Interestingly, CoVs have evolved elaborate strategies to evade the complex system of sensors and signalling molecules to suppress host immunity. SARS‐CoV‐2 papain‐like protease (PLpro), as an important coronavirus enzyme, regulates viral spread and innate immune responses. SCoV‐2 PLpro is multifunctional enzyme with deubiquitinating (DUB) and deISGylating activity. The PLpro can interact with key regulators in signalling pathways such as STING, NF‐κB, cytokine production, MAPK and TGF‐β and hijack those to block the immune responses. Therefore, the PLpro can be as an important target for the treatment of COVID‐19. Until now, several drugs or compounds have been identified that can inhibit PLpro activity. Here we discuss about the dysregulation effects of PLpro on immune system and drugs that have potential inhibitors for SCoV‐2 PLpro.